终端补充抑制剂拉武利祖马布用于一般化严重肌痛性
Tuan Vu1, Andreas Meisel2, Renato Mantegazza3
1University of South Florida Morsani College of Medicine, Tampa.
NEJM evidence
|February 6, 2024
概括
拉武利祖马布可为一般化肌痛性硬化症 (gMG) 患者提供快速和持续的症状改善. 这种补充抑制剂在日常活动和肌肉力量方面显示出显著的益处,而不会增加不良事件.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 一般化肌痛性肌痛症 (gMG) 是一种罕见的慢性自身免疫性疾病.
- 针对乙胆受体 (AChR) 的自身抗体激活补充,导致神经肌肉结损伤.
- 目前的治疗方法旨在控制症状和免疫反应.
研究的目的:
- 评估 ravulizumab,一个C5补充抑制剂,用于治疗抗AChR抗体阳性gMG.
- 在26周的时间内,评估ravulizumab与安慰剂相比的疗效和安全性.
主要方法:
- 一个随机的,双盲的,安慰剂控制的,跨国试验.
- 175名抗AChR抗体阳性gMG患者被随机分配 (1:1) 接受静脉注射拉武利祖马布或安慰剂.
- 治疗包括加重剂量,然后每8周服用一次维持剂量,持续26周.
主要成果:
- 与安慰剂相比,ravulizumab在患者报告的MG-ADL得分 (3.1与1.4;P<0.001) 和临床医生报告的QMG得分 (2.8与0.8;P<0.001) 中显示了统计学上显著的改善.
- 在一周内迅速观察到改善,并持续到26周.
- 较大比例的拉武利祖马布治疗患者 (30.0%) 在QMG得分上实现了≥5分的改善,而不是安慰剂 (11.3%;P=0.005).
结论:
- 拉武利祖马布在gMG中提供了快速,持续和临床上有意义的改善.
- 拉武利祖马布的安全性和耐受性概况支持其在抗AChR抗体阳性gMG的成年人中使用.
- 拉武利祖马布代表了对补充介导的gMG的有前途的治疗选择.
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
01:15Myasthenia Gravis: Diagnostic Tests
844
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
844
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K
01:31Skeletal Muscle Relaxants: Therapeutic Uses
487
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
487
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
682
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
682
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
422
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
422